Abstract
Monoclonal immunoglobulin, as a marker for monoclonal gammopathy, is evaluated by protein electrophoresis (PEP) and immunofixation electrophoresis (IFE). However, PEP and IFE are not satisfactory in sensitivity, objectivity, and facility. Recently, a highly sensitive, automated immunoassay for measurement of free light chain (FLC) concentrations in serum and urine has been developed for the identification and monitoring of patients with monoclonal gammopathy. To explore the clinical usefulness of measurement of FLC concentrations, we measured the κ and λ FLC concentrations and calculated the κ/λ FLC ratios for three groups [multiple myeloma (MM), other diseases, and control] and compared the results of the FLC assay with the results of PEP or IFE. The concentrations of serum κ and λ FLCs and the κ/λ FLC ratios for the MM group and non-MM groups were distinct. In the MM group, some sera and urine samples had no evidence of M protein on PEP and IFE, but FLC assay showed abnormal concentrations of FLCs and abnormal κ/λ FLC ratios in most cases. As compared with the PEP, the κ/λ FLC ratio revealed higher sensitivity in all diagnostic ranges with different cutoff values. Particularly, when the cutoff value 2.0 for κ/λ FLC ratio was used, specificity and positive predictive value were largely improved than when the cutoff values 1.2 and 1.5 were used. These findings indicated that FLC assay enables to detect myeloma patients with very low M protein due to early stage or after therapy and to distinguish patients with monoclonal increase of FLC from patients with polyclonal increase of FLC due to other conditions, particularly using κ/λ FLC ratio 0.3–2.0 as a diagnostic range. Despite some technical limitations of the assay, the incorporation of κ/λ FLC ratios with FLC concentrations is useful in the detection of M protein, particularly with negative serum or urine IFE results, and differentiation of monoclonal gammopathies from patients with polyclonal increase in FLC due to other conditions.
Similar content being viewed by others
References
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet 361:489–491
Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437–1444
Kyle RA (1999) Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 123:114–118
Alyanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P (2004) Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 75:246–248
Le Bricon T, Bengoufa D, Benlakehal M, Bousquet B, Erlich D (2002) Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma. Clin Biochem 35:565–567
Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, Katzmann JA (2002) Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 48:655–657
Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59
Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA (2003) Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274–278
Tate JR, Gill D, Cobcroft R, Hickman PE (2003) Practical considerations for the measurement of free light chains in serum. Clin Chem 49:1252–1257
Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900–2902
Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673–680
Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G (2001) Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114:822–829
Whicher JT, Warren C, Chambers RE (1984) Immunochemical assays for immunoglobulins. Ann Clin Biochem 21:78–91
Abraham RS, Charlesworth MC, Owen BAL, Benson LM, Katzmann JA, Reeder CB, Kyle RA (2002) Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 48:1805–1811
Mead GP, Stubbs PS, Carr-Smith HD, Drew RL, Bradwell AR (2002) Nephelometric measurement of serum free light chains in nonsecretory myeloma [Abstract]. Clin Chem 48(Suppl 6):A23
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kang, SY., Suh, JT., Lee, HJ. et al. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 84, 588–593 (2005). https://doi.org/10.1007/s00277-005-1047-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-005-1047-z